Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046989 | 0.87 | AKR1C3 (0.65) | HDAC6AKR1C3MEN1KMT2AESR2 | |
| SCHEMBL20046985 | 0.83 | AKR1C3 (0.60) | HDAC6AKR1C3MEN1KMT2AESR2 | |
| SCHEMBL2590065 | 0.83 | AKR1C3 (0.60) | HDAC6AKR1C3MEN1KMT2AESR2 | |
| SCHEMBL1264443 | 0.82 | HDAC6 (1.00) | HDAC6AKR1C3NAMPTHDAC1ALDH1A1 | |
| SCHEMBL20047144 | 0.81 | HDAC6 (0.61) | HDAC6AKR1C3NAMPTMEN1KMT2A | |
| SCHEMBL723811 | 0.81 | MEN1 (0.68) | HDAC6AKR1C3MEN1KMT2AESR2 | |
| SCHEMBL31745757 | 0.79 | ESR2 (0.58) | HDAC6AKR1C3NAMPTMEN1KMT2A | |
| SCHEMBL20047146 | 0.78 | HDAC6 (0.57) | HDAC6AKR1C3NAMPTMEN1KMT2A | |
| SCHEMBL31670441 | 0.78 | AKR1C3 (0.73) | AKR1C3MEN1KMT2AESR2PPARG | |
| SCHEMBL693876 | 0.78 | HDAC6 (0.56) | HDAC6AKR1C3NAMPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | NR1H2, NR1H3, PPARD | HDAC6 2050/4885AKR1C3 1019/4885NAMPT 1542/4885 |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | HDAC6 2050/4885AKR1C3 1019/4885NAMPT 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.